Drug Database · Clinicians

Sevoflurane

Brands (27) Sevotroy 250, Sitivorane, Aevosha…Show all

US brand (reference label): Ultane; not a Philippine-registered brand.

General Anesthetic US FDA class
General anesthetic (halogenated hydrocarbon); General anaesthetic PH FDA category

Rx · Prescription drug31 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c9aa6489-5a36-44ed-9512-b996833d82f7, version date February 12, 2025 (Ultane · AbbVie Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE ULTANE is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE ULTANE is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. ULTANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane should be used.

Contraindications

CONTRAINDICATIONS Known or suspected genetic susceptibility to malignant hyperthermia (see WARNINGS - Malignant Hyperthermia, CLINICAL PHARMACOLOGY - Pharmacogenomics). Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION The concentration of sevoflurane being delivered from a vaporizer should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient's response. Replacement of Desiccated CO 2 Absorbents When a clinician suspects that the CO 2 absorbent may be desiccated, it should be replaced.

The exothermic reaction that occurs with sevoflurane and CO 2 absorbents is increased when the CO 2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO 2 absorbent canisters (see PRECAUTIONS). Pre-anesthetic Medication No specific premedication is either indicated or contraindicated with sevoflurane.

The decision as to whether or not to premedicate and the choice of premedication is left to the discretion of the anesthesiologist. Induction Sevoflurane has a nonpungent odor and does not cause respiratory irritability; it is suitable for mask induction in pediatrics and adults. Maintenance Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide.

Sevoflurane can be administered with any type of anesthesia circuit. Table 9. MAC Values for Adults and Pediatric Patients According to Age Age of Patient (years) Sevoflurane in Oxygen Sevoflurane in 65% N 2 O/35% O 2 0 - 1 months # 3.3% 1 - < 6 months 3.0% 6 months - < 3 years 2.8% 2.0% @ 3 - 12 2.5% 25 2.6% 1.4% 40 2.1% 1.1% 60 1.7% 0.9% 80 1.4% 0.7% # Neonates are full-term gestational age.

MAC in premature infants has not been determined. @ In 1 - < 3 year old pediatric patients, 60% N 2 O/40% O 2 was used.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (clinical pharmacology)

Renal Impairment Sevoflurane was evaluated in renally impaired patients with baseline serum creatinine > 1.5 mg/dL. Fourteen patients who received sevoflurane were compared with 12 patients who received isoflurane. In another study, 21 patients who received sevoflurane were compared with 20 patients who received enflurane.

Creatinine levels increased in 7% of patients who received sevoflurane, 8% of patients who received isoflurane, and 10% of patients who received enflurane. Because of the small number of patients with renal insufficiency (baseline serum creatinine greater than 1.5 mg/dL) studied, the safety of sevoflurane administration in this group has not yet been fully established.

Therefore, sevoflurane should be used with caution in patients with renal insufficiency (see WARNINGS).

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Induction and maintenance of general anesthesia with sevoflurane have been established in controlled clinical studies in pediatric patients aged 1 to 18 years (see CLINICAL STUDIES, ADVERSE REACTIONS). Sevoflurane has a nonpungent odor and is suitable for mask induction in pediatric patients. The concentration of sevoflurane required for maintenance of general anesthesia is age dependent.

When used in combination with nitrous oxide, the MAC equivalent dose of sevoflurane should be reduced in pediatric patients. MAC in premature infants has not been determined (see PRECAUTIONS - Drug Interactions, DOSAGE AND ADMINISTRATION for recommendations in pediatric patients 1 day of age and older). The use of sevoflurane has been associated with seizures (see PRECAUTIONS, ADVERSE REACTIONS).

The majority of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgement should be exercised when using sevoflurane in patients who may be at risk for seizures. Cases of life-threatening ventricular arrhythmias have been reported in pediatric patients with Pompe disease (also commonly known as glycogen storage disease type II or acid maltase deficiency).

In a published case series about a clinical trial of patients with infantile-onset Pompe disease, six percent of patients (9 of 139, with 6 of 9 having received sevoflurane) experienced arrhythmias after induction of anesthesia. Reported arrhythmias included severe bradycardia, torsade de pointes, and fatal ventricular fibrillation, which usually resolved after treatment with pharmacologic agents and defibrillation.

Avoid induction and maintenance of anesthesia using sole agents, such as sevoflurane, that decrease systemic vascular resistance or diastolic blood pressure. Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as ULTANE, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis.

Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately 3 years of age in humans. In primates, exposure to 3 hours of ketamine that produced a light surgical plane of anesthesia did not increase neuronal cell loss; however, treatment regimens of 5 hours or longer of isoflurane increased neuronal cell loss.

Data from isoflurane-treated rodents and ketamine-treated primates suggest that the neuronal and oligodendrocyte cell losses are associated with prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in pregnant women, neonates, and young children who require procedures with the potential risks suggested by the nonclinical data (see WARNINGS - Pediatric Neurotoxicity, PRECAUTIONS - Pregnancy, ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY).

Use in Pediatric Patients with Down Syndrome See WARNINGS - Bradycardia in Down Syndrome.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old.

Dosage forms

Philippines

  • Liquid for inhalation: 250 mL

Registered products in the Philippines

31 products registered with the Food and Drug Administration (FDA) Philippines list Sevoflurane as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products31
Philippine FDA-registered products for Sevoflurane
Package insert
AevoshaSevoflurane
100% v/v Volatile Liquid for InhalationType III amber glass bottle with collar on the neck, sealed with a poly-seal cap, and secured with PET film x 250 mL (Box of 1 's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Dynasty PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-8990-03
Jul 26, 2031
BesfluranSevoflurane
250 mL (100%) Liquid for InhalationUSP Type III amber glass bottle with bottle cap and yellow collar pin x 250 mL Box of 1's
Rx
Singapore Pharmawealth Lifesciences, IncPhilippines
—
DR-XY44908 (FOR EXPORT ONLY)
Nov 13, 2030
CentraneSevoflurane
100% v/v Volatile Liquid for InhalationUSP Type III Amber Glass Bottle with poly-seal cone lined cap x 250 mL (Box of 1's)
Rx
Hana Pharmaceutical Co., Ltd.Republic of Korea
Central West MedicaleImporter: JLT Pharma, Inc.
DRP-11095-02
Jan 28, 2027
FlorexSevoflurane
100% v/v Volatile Liquid for InhalationUSP Type III Amber Glass bottle with poly-seal cone lined cap x 250mL (Box of 1's)
Rx
Hana Pharmaceutical Co., Ltd.Republic of Korea
IMJ Medica Inc.Importer: JLT Pharma Inc.
DRP-11095-03
Jan 28, 2027
FlosevSevoflurane
100% v/v Volatile Liquid For InhalationType I amber glass bottle closed with a polypropylene screw cap and sealed with a polyethylene seal x 250 mL (Box of 1's)
Rx
lsung Pharmaceuticals Co, Ltd.Korea
Shalaks Pharmaceuticals, Inc.
DRP-11098
Jan 28, 2027
NishafluraneSevoflurane
100% v/v Volatile Liquid for InhalationType III amber glass bottle with a collar on the neck, sealed with a poly-seal cap, and secured with PET film x 250 mL (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-8990-02
Jun 2, 2031
NoneSevoflurane
100% w/w Volatile Liquid for InhalationAluminum Bottle x 250 mL
Rx
Baxter Healthcare CorporationPuerto Rico
Baxter Healthcare Philippines Inc.Trader: Baxter Healthcare Corporation
DR-XY34788
Aug 12, 2028
NorevellSevoflurane
100% Liquid for InhalationType III Amber colored glass bottle with black phenolic cap and yellow LDPE bottle collar x 250 mL (Box of 1's)
Rx
PT. Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY49332
Feb 11, 2030
QurvaneSevoflurane
100% v/v Volatile Liquid for InhalationUSP Type III Amber Glass bottle with poly-seal cone lined cap x 250 mL (Box of 1's)
Rx
Hana Pharmaceutical Co., Ltd.Republic of Korea
Amediqo Phils., Inc.Importer: JLT Pharma Inc.
DRP-11095-01
Jan 28, 2027
SevoSevoflurane
100% Liquid For InhalationPolyethylene naphthalate (PEN) amber bottle HDPE universal snap type adaptor x 250 mL (Box of 1’s)
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
Endure Medical, Inc.
DR-XY35216
Nov 4, 2031
Sevo-AnesteranSevoflurane
100% Liquid for Inhalation100 mL and 250 mL USP Type III Amber glass Bottle (Box of 1's)
Rx
S.C. Rompharma Company SrlRomania
I.E Medica Inc.Trader: Nobilis PTE Ltd.
DRP-12379
Feb 9, 2037
SevoflexSevoflurane
100% v/v Liquid for InhalationUSP Type III amber glass bottle with 24-400 black custom closure with polyseal liner x 250 mL (Box of 1's)
Rx
Shanghai Hengrui Pharmaceutical Co., Ltd.China
Phil. Pharmawealth, Inc.
DR-XY48033
May 20, 2027
SevofranSevoflurane
100% v/v Volatile Liquid For InhalationUSP Type III Amber Glass bottle with poly-seal cone lined cap x 250 mL (Box of l's)
Rx
Hana Pharmaceutical Co., Ltd.Korea
JLT Pharma, Inc.
DRP-11095
Jan 28, 2027
SevohealSevoflurane
100% v/v Volatile Liquid for InhalationType III amber glass bottle with collar on the neck, sealed with a poly-seal cap, and secured with PET film x 250 mL (Box of 1 's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
MSF Pharmaceutical Products DistributionImporter: AMB HK Enterprises Inc.
DRP-8990-01
Aug 18, 2031
SevolemSevoflurane
100% v/v Volatile Liquid for InhalationUSP Type III Amber Glass bottle with poly-seal cone lined cap x 250 mL (Box of 1's)
Rx
Hana Pharmaceutical Co., Ltd.Republic of Korea
L.E.M. Pharma and Medical Supplies TradingImporter: JLT Pharma Inc.
DRP-11095-05
Jan 28, 2027
SevollenSevoflurane
100% v/v Volatile Liquid For InhalationUSP Type III amber glass bottle x 100 mL and 250 mL with Aluminum LDPE liner combined cap and lantern ring
Rx
Enicar Pharmaceuticals Pvt. Ltd.India
Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-14866
Jan 29, 2029
SevomedSevoflurane
100% Volatile Liquid for Inhalation250 mL USP Type III amber glass bottle with aluminum and LDPE liner combined cap and HDPE lantern ring (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Ellebasy Medicale TradingImporter: Sahar International trading, Inc.
DRP-9921-02
Jan 16, 2030
SevomondSevoflurane
100 % v/v Volatile Liquid for InhalationUSP Type III Amber Glass bottle with poly-seal cone lined cap x 250 mL (Box of 1's)
Rx
Hana Pharmaceutical Co., Ltd.Republic of Korea
Mondeglobal Trading CorporationImporter: JLT Pharma Inc.
DRP-11095-04
Jan 28, 2027
SevoraneSevoflurane
100% Liquid for Inhalation (Wet Formulation)250 Amber Polyethylene Naphthalate Bottle with Quik-Fil Cap in a box
Rx
AbbVie S.r.L.Italy
Importer: ZUELLIG PHARMA CORPORATION
DR-XY31826
Nov 15, 2028
SevorizzSevoflurane
100 % Volatile Liquid for Inhalation250 mL USP Type III amber glass bottle with aluminum and LDPE liner combined cap and HDPE lantern ring (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Amson PharmaceuticalsImporter: Sahar International Trading, Inc.
DRP-9921-03
Jan 16, 2030
SevosaphraneSevoflurane
100% v/v Volatile Liquid For InhalationUSP Type III amber bottle x 100 mL and 250 mL with aluminum and LDPE liner combined cap and HDPE lantern ring (Box of 1's)
Rx
Althea Pharma Pvt. Ltd.India
Nelpa Lifesciences Inc.
DRP-14764
Jan 2, 2029
SevoshaSevoflurane
100 % Volatile Liquid for Inhalation250 mL USP Type III amber glass bottle with aluminum and LDPE liner combined cap and HDPE lantern ring (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., LtdChina
One Dexcel Pharma Inc.Importer: Sahar International Trading, Inc.
DRP-9921-04
Jan 16, 2030
SevotaneSevoflurane
100% v/v Volatile Liquid for InhalationType III amber glass bottle with a collar on the neck, sealed with a poly-seal cap, and secured with PET film x 250 mL (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Twostar Pharmaceutical TradingImporter: AMB HK Enterprises Inc.
DRP-8990
Jul 23, 2031
Sevotroy 250Sevoflurane
100% v/v Volatile Liquid for InhalationType III Amber Color Glass Bottle with Black Cap Sealed with LDPEP Plastic-U Plug and Yellow Ring Pull x 250 mL (Box of 1's)
Rx
Troikaa Pharmaceuticals, Ltd.India
Troikaa Pharmaceuticals Philippines Inc.Importer: Troikaa Pharmaceuticals Philippines, Inc.
DRP-15092
Mar 14, 2029
Sevotroy 250Sevoflurane
100% v/v Volatile Liquid for Inhalation.Type III Amber Color Glass Bottle with Black Cap Sealed with LDPE Plastic-U Plug and Yellow Ring Pull x 250 mL (Box of 1's)
Rx
Troikaa Pharmaceuticals, Ltd.India
Troikaa Pharmaceuticals Philippines, Inc.
DR- XY49022
Mar 14, 2029
SevoxaneSevoflurane
100% Liquid for InhalationUSP Type III Amber Glass Bottle x 250 mL
Rx
SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.China
NUEVA SUNSHINE PHILS., INC.
DRP-8704
Feb 7, 2030
SitivoraneSevoflurane
100 % Volatile Liquid for Inhalation250 mL USP Type III Amber Glass Bottle with aluminum and LDPE liner combined cap and HDPE lantern ring (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Buehler Pharma and Medical Trading Corp.Importer: Sahar International Trading Inc.
DRP-9921-05
Jan 16, 2030
SitivoraneSevoflurane
100% Volatile Liquid for Inhalation250 mL USP Type III Amber Glass Bottle with aluminum and LDPE liner combined cap and HDPE lantern ring (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Sahar International Trading Inc.
DRP-9921
Jan 16, 2030
SojournSevoflurane
100% v/v Volatile Liquid for InhalationType III Amber Glass Bottle x 250 mL (net content) (Box of 1's)
Rx
Piramal Critical CareUSA
Fresenius Kabi Philippines, Inc.
DR-XY41989
Apr 30, 2031
THEREmaxSevoflurane
100% Volatile Liquid for Inhalation250 mL USP Type III Amber Glass Bottle with Aluminum and LDPE Liner Combined Cap and HDPE Lantern Ring (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Amson PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-9921-01
Jan 16, 2030
(no brand name)Sevoflurane
100 % v/v Volatile Liquid For InhalationType III Amber Glass Bottle in 250 mL
Rx
Piramal Pharma Limited.India
Importer: Fresenius Kabi Philippines, Inc.
DRP-2089
Apr 13, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Risk of Renal Injury Although data from controlled clinical studies at low flow rates are limited, findings taken from patient and animal studies suggest that there is a potential for renal injury which is presumed due to Compound A. Animal and human studies demonstrate that sevoflurane administered for more than 2 MAC·hours and at fresh gas flow rates of < 2 L/min may be associated with proteinuria and glycosuria.

While a level of Compound A exposure at which clinical nephrotoxicity might be expected to occur has not been established, it is prudent to consider all of the factors leading to Compound A exposure in humans, especially duration of exposure, fresh gas flow rate, and concentration of sevoflurane. During sevoflurane anesthesia the clinician should adjust inspired concentration and fresh gas flow rate to minimize exposure to Compound A.

To minimize exposure to Compound A, sevoflurane exposure should not exceed 2 MAC·hours at flow rates of 1 to < 2 L/min. Fresh gas flow rates < 1 L/min are not recommended. Because clinical experience in administering sevoflurane to patients with renal insufficiency (creatinine > 1.5 mg/dL) is limited, its safety in these patients has not been established.

Sevoflurane may be associated with glycosuria and proteinuria when used for long procedures at low flow rates. The safety of low flow sevoflurane on renal function was evaluated in patients with normal preoperative renal function. One study compared sevoflurane (N = 98) to an active control (N = 90) administered for ≥ 2 hours at a fresh gas flow rate of ≤ 1 Liter/minute.

Per study defined criteria, one patient in the sevoflurane group developed elevations of creatinine, in addition to glycosuria and proteinuria. This patient received sevoflurane at fresh gas flow rates of ≤ 800 mL/minute. Using these same criteria, there were no patients in the active control group who developed treatment emergent elevations in serum creatinine.

Sevoflurane may present an increased risk in patients with known sensitivity to volatile halogenated anesthetic agents. KOH containing CO 2 absorbents are not recommended for use with sevoflurane. Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression.

Monitor respiration and, if necessary, assist with ventilation (see PRECAUTIONS). Risk of QT Prolongation Reports of QT prolongation, associated with torsade de pointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval).

Malignant Hyperthermia In susceptible individuals, volatile anesthetic agents, including sevoflurane, may trigger malignant hyperthermia, a skeletal muscle hypermetabolic state leading to high oxygen demand. Fatal outcomes of malignant hyperthermia have been reported. In clinical studies of ULTANE, 1 case of malignant hyperthermia was reported.

The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. ULTANE can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants (see CONTRAINDICATIONS, CLINICAL PHARMACOLOGY - Pharmacogenomics).

Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia, hypercapnia, muscle rigidity (e.g., jaw muscle spasm), tachycardia (e.g., particularly that unresponsive to deepening anesthesia or analgesic medication administration), tachypnea, cyanosis, arrhythmias, hypovolemia, and hemodynamic instability. Skin mottling, coagulopathies, and renal failure may occur later in the course of the hypermetabolic process.

Successful treatment of malignant hyperthermia depends on early recognition of the clinical signs. If malignant hyperthermia is suspected, discontinue all triggering agents (i.e., volatile anesthetic agents and succinylcholine), administer intravenous dantrolene sodium, and initiate supportive therapies. Consult prescribing information for intravenous dantrolene sodium for additional information on patient management.

Supportive therapies include administration of supplemental oxygen and respiratory support based on clinical need, maintenance of hemodynamic stability and adequate urinary output, management of fluid and electrolyte balance, correction of acid base derangements, and institution of measures to control rising temperature. Perioperative Hyperkalemia Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period.

Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria.

Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended as is subsequent evaluation for latent neuromuscular disease.

Pediatric Neurotoxicity Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear.

However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans (see PRECAUTIONS - Pregnancy, PRECAUTIONS - Pediatric Use, ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY). Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects.

These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness. Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other.

Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks. Bradycardia in Down Syndrome Episodes of severe bradycardia and cardiac arrest, not related to underlying congenital heart disease, have been reported during anesthesia induction with sevoflurane in pediatric patients with Down syndrome.

In most cases, bradycardia improved with decreasing the concentration of sevoflurane, manipulating the airway, or administering an anticholinergic or epinephrine. During induction, closely monitor heart rate, and consider incrementally increasing the inspired sevoflurane concentration until a suitable level of anesthesia is achieved.

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. Risk of Driving and Operating Machinery Performance of activities requiring mental alertness, such as driving or operating machinery, may be impaired after sevoflurane anesthesia.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias.

Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane.

In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitantly. Succinylcholine See WARNINGS - Perioperative Hyperkalemia. Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures.

Intravenous Anesthetics Sevoflurane administration is compatible with barbiturates, propofol, and other commonly used intravenous anesthetics. Benzodiazepines and Opioids Benzodiazepines and opioids would be expected to decrease the MAC of sevoflurane in the same manner as with other inhalational anesthetics. Sevoflurane administration is compatible with benzodiazepines and opioids as commonly used in surgical practice.

Nitrous Oxide As with other halogenated volatile anesthetics, the anesthetic requirement for sevoflurane is decreased when administered in combination with nitrous oxide. Using 50% N 2 O, the MAC equivalent dose requirement is reduced approximately 50% in adults, and approximately 25% in pediatric patients (see DOSAGE AND ADMINISTRATION).

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. When used to supplement alfentanil-N 2 O anesthesia, sevoflurane and isoflurane equally potentiate neuromuscular block induced with pancuronium, vecuronium or atracurium.

Therefore, during sevoflurane anesthesia, the dosage adjustments for these muscle relaxants are similar to those required with isoflurane. Potentiation of neuromuscular blocking agents requires equilibration of muscle with delivered partial pressure of sevoflurane. Reduced doses of neuromuscular blocking agents during induction of anesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate muscle relaxation.

Among available nondepolarizing agents, only vecuronium, pancuronium and atracurium interactions have been studied during sevoflurane anesthesia. In the absence of specific guidelines: For endotracheal intubation, do not reduce the dose of nondepolarizing muscle relaxants. During maintenance of anesthesia, the required dose of nondepolarizing muscle relaxants is likely to be reduced compared to that during N 2 O/opioid anesthesia.

Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation. The effect of sevoflurane on the duration of depolarizing neuromuscular blockade induced by succinylcholine has not been studied.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Clinical Trials Experience Adverse events are derived from controlled clinical studies conducted in the United States, Canada, and Europe. The reference drugs were isoflurane, enflurane, and propofol in adults and halothane in pediatric patients. The studies were conducted using a variety of premedications, other anesthetics, and surgical procedures of varying length.

Most adverse events reported were mild and transient, and may reflect the surgical procedures, patient characteristics (including disease) and/or medications administered. Of the 5182 patients enrolled in the clinical studies, 2906 were exposed to sevoflurane, including 118 adults and 507 pediatric patients who underwent mask induction.

Each patient was counted once for each type of adverse event. Adverse events reported in patients in clinical studies and considered to be possibly or probably related to sevoflurane are presented within each body system in order of decreasing frequency in the following listings. One case of malignant hyperthermia was reported in pre-registration clinical studies.

Adverse Events During the Induction Period (from Onset of Anesthesia by Mask Induction to Surgical Incision) Incidence > 1% Adult Patients (N = 118) Cardiovascular Bradycardia 5%, Hypotension 4%, Tachycardia 2% Nervous System Agitation 7% Respiratory System Laryngospasm 8%, Airway obstruction 8%, Breathholding 5%, Cough Increased 5% Pediatric Patients (N = 507) Cardiovascular Tachycardia 6%, Hypotension 4% Nervous System Agitation 15% Respiratory System Breathholding 5%, Cough Increased 5%, Laryngospasm 3%, Apnea 2% Digestive System Increased salivation 2% Adverse Events During Maintenance and Emergence Periods, Incidence > 1% (N = 2906) Body as a whole Fever 1%, Shivering 6%, Hypothermia 1%, Movement 1%, Headache 1% Cardiovascular Hypotension 11%, Hypertension 2%, Bradycardia 5%, Tachycardia 2% Nervous System Somnolence 9%, Agitation 9%, Dizziness 4%, Increased salivation 4% Digestive System Nausea 25%, Vomiting 18% Respiratory System Cough increased 11%, Breathholding 2%, Laryngospasm 2% Adverse Events, All Patients in Clinical Studies (N = 2906), All Anesthetic Periods, Incidence < 1% (Reported in 3 or More Patients) Body as a whole Asthenia, Pain Cardiovascular Arrhythmia, Ventricular Extrasystoles, Supraventricular Extrasystoles, Complete AV Block, Bigeminy, Hemorrhage, Inverted T Wave, Atrial Fibrillation, Atrial Arrhythmia, Second Degree AV Block, Syncope, S-T Depressed Nervous System Crying, Nervousness, Confusion, Hypertonia, Dry Mouth, Insomnia Respiratory System Sputum Increased, Apnea, Hypoxia, Wheezing, Bronchospasm, Hyperventilation, Pharyngitis, Hiccup, Hypoventilation, Dyspnea, Stridor Metabolism and Nutrition Increases in LDH, AST, ALT, BUN, Alkaline Phosphatase, Creatinine, Bilirubinemia, Glycosuria, Fluorosis, Albuminuria, Hypophosphatemia, Acidosis, Hyperglycemia Hemic and Lymphatic System Leucocytosis, Thrombocytopenia Skin and Special Senses Amblyopia, Pruritus, Taste Perversion, Rash, Conjunctivitis Urogenital Urination Impaired, Urine Abnormality, Urinary Retention, Oliguria See WARNINGS for information regarding malignant hyperthermia. Post m arketing Experience The following adverse events have been identified during post-approval use of Ultane (sevoflurane USP).

Due to the spontaneous nature of these reports, the actual incidence and relationship of Ultane to these events cannot be established with certainty. Central Nervous System Seizures: Postmarketing reports indicate that sevoflurane use has been associated with seizures. The majority of cases were in children and young adults, most of whom had no medical history of seizures.

Several cases reported no concomitant medications, and at least one case was confirmed by EEG. Although many cases were single seizures that resolved spontaneously or after treatment, cases of multiple seizures have also been reported. Seizures have occurred during, or soon after sevoflurane induction, during emergence, and during post-operative recovery up to a day following anesthesia.

Delirium Cardiac Cardiac arrest QT prolongation associated with Torsade de Pointe Bradycardia in patients with Down syndrome Pulmonary Diffuse Alveolar Hemorrhage: Hemoptysis, shortness of breath with chest X-ray findings, and increasing aliquots of frank blood on bronchoalveolar lavage have been reported following exposure to sevoflurane and in the absence of observed airway obstruction. Hepatic Cases of mild, moderate and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported.

Histological evidence was not provided for any of the reported hepatitis cases. In most of these cases, patients had underlying hepatic conditions or were under treatment with drugs known to cause hepatic dysfunction. Most of the reported events were transient and resolved spontaneously (see PRECAUTIONS). Hepatic necrosis Hepatic failure Other Malignant hyperthermia (see CONTRAINDICATIONS, WARNINGS) Allergic reactions, such as rash, urticaria, pruritus, bronchospasm, and anaphylactic reactions (see CONTRAINDICATIONS) Reports of hypersensitivity (including contact dermatitis, rash, dyspnea, wheezing, chest discomfort, swelling face, or anaphylactic reaction) have been received, particularly in association with long-term occupational exposure to inhaled anesthetic agents, including sevoflurane (see SAFETY AND HANDLING - Occupational Caution).

Laboratory Findings Transient elevations in glucose, liver function tests, and white blood cell count may occur as with use of other anesthetic agents.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, reduced fetal weights were noted following exposure to 1 MAC sevoflurane for three hours a day during organogenesis. Developmental and reproductive toxicity studies of sevoflurane in animals in the presence of strong alkalies (i.e., degradation of sevoflurane and production of Compound A) have not been conducted.

Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data Animal Data Pregnant rats were treated with sevoflurane (0.22%, 0.66%, or 2.2% equals 0.1, 0.3, or 1.0 MAC) without CO 2 absorbent for three hours per day during organogenesis (from Gestation Day 7 to 17). Fetuses obtained by Cesarean section were examined on Gestation Day 20 while some animals were maintained for littering and pups were examined for adverse effects.

There were no adverse effects on fetuses at 0.3 MAC. Reduced fetal body weights and increased skeletal variations such as delayed ossifications in the presence of maternal toxicity (reduced food and water intake and body weight of the dams) were noted at 1 MAC. In dams allowed to litter, reduced pup bodyweight gain and evidence of developmental delays (slight delay in eyelid opening and increased incidence of nonreactive animals in the visual placing reflex test) were noted in the 1.0 MAC treatment group.

Pregnant rabbits were treated with sevoflurane (0.1, 0.3, or 1.0 MAC) without CO 2 absorbent for three hours per day during organogenesis (from Gestation Day 6 to 18). There were no adverse effects on the fetus at any dose; the mid- and high-dose produced a 5% and 6% decrease in maternal body weight, respectively. In another study, pregnant rats were administered sevoflurane (0.1, 0.3, or 1.0 MAC) from Gestation Day 17 to Postnatal Day 21.

Pup body weights were reduced in the 1.0 MAC treatment group in the absence of maternal toxicity. There was no effect of sevoflurane on sensory function (visual, auditory, nociception, righting reflexes), motor (roto-rod), open field test, or learning tasks (shuttle box avoidance and water T-maze). In a published study in primates, administration of an anesthetic dose of ketamine for 24 hours on Gestation Day 122 increased neuronal apoptosis in the developing brain of the fetus.

In other published studies, administration of either isoflurane or propofol for 5 hours on Gestation Day 120 resulted in increased neuronal and oligodendrocyte apoptosis in the developing brain of the offspring. With respect to brain development, this time period corresponds to the third trimester of gestation in the human.

The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits (see WARNINGS - Pediatric Neurotoxicity, PRECAUTIONS - Pediatric Use, ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY).

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether sevoflurane or its metabolites are present in human milk. To minimize infant exposure to sevoflurane or its metabolites, a nursing mother may temporarily pump, and discard breast milk produced during the first 24 hours after administration of sevoflurane. Exercise caution when administering sevoflurane to a nursing mother.

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

Pharmacodynamics Changes in the depth of sevoflurane anesthesia rapidly follow changes in the inspired concentration. In the sevoflurane clinical program, the following recovery variables were evaluated: 1. Time to events measured from the end of study drug: Time to removal of the endotracheal tube (extubation time) Time required for the patient to open his/her eyes on verbal command (emergence time) Time to respond to simple command (e.g., squeeze my hand) or demonstrates purposeful movement (response to command time, orientation time) 2.

Recovery of cognitive function and motor coordination was evaluated based on: psychomotor performance tests (Digit Symbol Substitution Test [DSST], Trieger Dot Test) the results of subjective (Visual Analog Scale [VAS]) and objective (objective pain-discomfort scale [OPDS]) measurements time to administration of the first post-anesthesia analgesic medication assessments of post-anesthesia patient status 3. Other recovery times were: time to achieve an Aldrete Score of ≥ 8 time required for the patient to be eligible for discharge from the recovery area, per standard criteria at site time when the patient was eligible for discharge from the hospital time when the patient was able to sit up or stand without dizziness Some of these variables are summarized as follows: Table 2.

Induction and Recovery Variables for Evaluable Pediatric Patients in Two Comparative Studies: Sevoflurane versus Halothane Time to End-Point (min) Sevoflurane Mean ± SEM Halothane Mean ± SEM Induction 2.0 ± 0.2 (n = 294) 2.7 ± 0.2 (n = 252) Emergence 11.3 ± 0.7 (n = 293) 15.8 ± 0.8 (n = 252) Response to command 13.7 ± 1.0 (n = 271) 19.3 ± 1.1 (n = 230) First analgesia 52.2 ± 8.5 (n = 216) 67.6 ± 10.6 (n = 150) Eligible for recovery discharge 76.5 ± 2.0 (n = 292) 81.1 ± 1.9 (n = 246) n = number of patients with recording of events. Table 3.

Recovery Variables for Evaluable Adult Patients in Two Comparative Studies: Sevoflurane versus Isoflurane Time to Parameter: (min) Sevoflurane Mean ± SEM Isoflurane Mean ± SEM Emergence 7.7 ± 0.3 (n = 395) 9.1 ± 0.3 (n = 348) Response to command 8.1 ± 0.3 (n = 395) 9.7 ± 0.3 (n = 345) First analgesia 42.7 ± 3.0 (n = 269) 52.9 ± 4.2 (n = 228) Eligible for recovery discharge 87.6 ± 5.3 (n = 244) 79.1 ± 5.2 (n = 252) n = number of patients with recording of recovery events. Table 4.

Meta-Analyses for Induction and Emergence Variables for Evaluable Adult Patients in Comparative Studies: Sevoflurane versus Propofol Parameter No. of Studies Sevoflurane Mean ± SEM Propofol Mean ± SEM Mean maintenance anesthesia 3 1.0 MAC·hr. ± 0.8 7.2 mg/kg/hr ± 2.6 exposure (n = 259) (n = 258) Time to induction: (min) 1 3.1 ± 0.18* 2.2 ± 0.18** (n = 93) (n = 93) Time to emergence: (min) 3 8.6 ± 0.57 11.0 ± 0.57 (n = 255) (n = 260) Time to respond to command: (min) 3 9.9 ± 0.60 12.1 ± 0.60 (n = 257) (n = 260) Time to first analgesia: (min) 3 43.8 ± 3.79 57.9 ± 3.68 (n = 177) (n = 179) Time to eligibility for recovery 3 116.0 ± 4.15 115.6 ± 3.98 discharge: (min) (n = 257) (n = 261) * Propofol induction of one sevoflurane group = mean of 178.8 mg ± 72.5 SD (n = 165) ** Propofol induction of all propofol groups = mean of 170.2 mg ± 60.6 SD (n = 245) n = number of patients with recording of events. Cardiovascular Effects Sevoflurane was studied in 14 healthy volunteers (18-35 years old) comparing sevoflurane-O 2 (Sevo/O 2) to sevoflurane-N 2 O/O 2 (Sevo/N 2 O/O 2) during 7 hours of anesthesia.

During controlled ventilation, hemodynamic parameters measured are shown in Figures 7-10: Figure 7. Heart Rate Figure 8. Mean Arterial Pressure Figure 9. Systemic Vascular Resistance Figure 10. Cardiac Index Sevoflurane is a dose-related cardiac depressant. Sevoflurane does not produce increases in heart rate at doses less than 2 MAC.

A study investigating the epinephrine induced arrhythmogenic effect of sevoflurane versus isoflurane in adult patients undergoing transsphenoidal hypophysectomy demonstrated that the threshold dose of epinephrine (i.e., the dose at which the first sign of arrhythmia was observed) producing multiple ventricular arrhythmias was 5 mcg/kg with both sevoflurane and isoflurane. Consequently, the interaction of sevoflurane with epinephrine appears to be equal to that seen with isoflurane.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Once formed HFIP is rapidly conjugated with glucuronic acid and eliminated as a urinary metabolite.

The half-life is in the range of 15-23 hours.

Compared with healthy individuals, the fluoride ion half-life was prolonged in patients with renal impairment, but not in the elderly.

A study in 8 patients with hepatic impairment suggests a slight prolongation of the half-life.

The mean half-life in patients with renal impairment averaged approximately 33 hours (range 21-61 hours) as compared to a mean of approximately 21 hours (range 10-48 hours) in normal healthy individuals.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics Uptake and Distribution Solubility Because of the low solubility of sevoflurane in blood (blood/gas partition coefficient @ 37°C = 0.63-0.69), a minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure. Therefore, there is a rapid rate of increase in the alveolar (end-tidal) concentration (F A) toward the inspired concentration (F I) during induction.

Induction of Anesthesia In a study in which seven healthy male volunteers were administered 70% N 2 O/30%O 2 for 30 minutes followed by 1.0% sevoflurane and 0.6% isoflurane for another 30 minutes the F A /F I ratio was greater for sevoflurane than isoflurane at all time points. The time for the concentration in the alveoli to reach 50% of the inspired concentration was 4-8 minutes for isoflurane and approximately 1 minute for sevoflurane.

F A /F I data from this study were compared with F A /F I data of other halogenated anesthetic agents from another study. When all data were normalized to isoflurane, the uptake and distribution of sevoflurane was shown to be faster than isoflurane and halothane, but slower than desflurane. The results are depicted in Figure 3.

Recovery from Anesthesia The low solubility of sevoflurane facilitates rapid elimination via the lungs. The rate of elimination is quantified as the rate of change of the alveolar (end-tidal) concentration following termination of anesthesia (F A), relative to the last alveolar concentration (Fa O) measured immediately before discontinuance of the anesthetic.

In the healthy volunteer study described above, rate of elimination of sevoflurane was similar compared with desflurane, but faster compared with either halothane or isoflurane. These results are depicted in Figure 4. Figure 3. Ratio of Concentration of Anesthetic in Alveolar Gas to Inspired Gas Figure 4. Concentration of Anesthetic in Alveolar Gas Following Termination of Anesthesia Protein Binding The effects of sevoflurane on the displacement of drugs from serum and tissue proteins have not been investigated.

Other fluorinated volatile anesthetics have been shown to displace drugs from serum and tissue proteins in vitro. The clinical significance of this is unknown. Clinical studies have shown no untoward effects when sevoflurane is administered to patients taking drugs that are highly bound and have a small volume of distribution (e.g., phenytoin).

Metabolism Sevoflurane is metabolized by cytochrome P450 2E1, to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO 2. Once formed HFIP is rapidly conjugated with glucuronic acid and eliminated as a urinary metabolite. No other metabolic pathways for sevoflurane have been identified. In vivo metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized.

Cytochrome P450 2E1 is the principal isoform identified for sevoflurane metabolism and this may be induced by chronic exposure to isoniazid and ethanol. This is similar to the metabolism of isoflurane and enflurane and is distinct from that of methoxyflurane which is metabolized via a variety of cytochrome P450 isoforms.

The metabolism of sevoflurane is not inducible by barbiturates. As shown in Figure 5, inorganic fluoride concentrations peak within 2 hours of the end of sevoflurane anesthesia and return to baseline concentrations within 48 hours post-anesthesia in the majority of cases (67%). The rapid and extensive pulmonary elimination of sevoflurane minimizes the amount of anesthetic available for metabolism.

Figure 5. Serum Inorganic Fluoride Concentrations for Sevoflurane and Other Volatile Anesthetics Legend: Pre-Anesth. = Pre-anesthesia Elimination Up to 3.5% of the sevoflurane dose appears in the urine as inorganic fluoride. Studies on fluoride indicate that up to 50% of fluoride clearance is nonrenal (via fluoride being taken up into bone).

Pharmacokinetics of Fluoride Ion Fluoride ion concentrations are influenced by the duration of anesthesia, the concentration of sevoflurane administered, and the composition of the anesthetic gas mixture. In studies where anesthesia was maintained purely with sevoflurane for periods ranging from 1 to 6 hours, peak fluoride concentrations ranged between 12 µM and 90 µM.

As shown in Figure 6, peak concentrations occur within 2 hours of the end of anesthesia and are less than 25 µM (475 ng/mL) for the majority of the population after 10 hours. The half-life is in the range of 15-23 hours. It has been reported that following administration of methoxyflurane, serum inorganic fluoride concentrations > 50 µM were correlated with the development of vasopressin-resistant, polyuric, renal failure.

In clinical studies with sevoflurane, there were no reports of toxicity associated with elevated fluoride ion levels. Figure 6. Fluoride Ion Concentrations Following Administration of Sevoflurane (mean MAC = 1.27, mean duration = 2.06 hr) Mean Fluoride Ion Concentrations (n = 48) Fluoride Concentrations After Repeat Exposure and in Special Populations Fluoride concentrations have been measured after single, extended, and repeat exposure to sevoflurane in normal surgical and special patient populations, and pharmacokinetic parameters were determined.

Compared with healthy individuals, the fluoride ion half-life was prolonged in patients with renal impairment, but not in the elderly. A study in 8 patients with hepatic impairment suggests a slight prolongation of the half-life. The mean half-life in patients with renal impairment averaged approximately 33 hours (range 21-61 hours) as compared to a mean of approximately 21 hours (range 10-48 hours) in normal healthy individuals.

The mean half-life in the elderly (greater than 65 years) approximated 24 hours (range 18-72 hours). The mean half-life in individuals with hepatic impairment was 23 hours (range 16-47 hours). Mean maximal fluoride values (C max) determined in individual studies of special populations are displayed below. Table 1. Fluoride Ion Estimates in Special Populations Following Administration of Sevoflurane n Age (yr) Duration (hr) Dose (MAC·hr) C max (µM) PEDIATRIC PATIENTS Anesthetic Sevoflurane-O 2 76 0-11 0.8 1.1 12.6 Sevoflurane-O 2 40 1-11 2.2 3.0 16.0 Sevoflurane/N 2 O 25 5-13 1.9 2.4 21.3 Sevoflurane/N 2 O 42 0-18 2.4 2.2 18.4 Sevoflurane/N 2 O 40 1-11 2.0 2.6 15.5 ELDERLY 33 65-93 2.6 1.4 25.6 RENAL 21 29-83 2.5 1.0 26.1 HEPATIC 8 42-79 3.6 2.2 30.6 OBESE 35 24-73 3.0 1.7 38.0 n = number of patients studied.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Sevoflurane 250 mL Bottle₱3,673.00–₱11,000.00Reference ₱4,433.11per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Sevoflurane
PNF listingInhalation: 250 mL bottleRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Ultane · AbbVie Inc. [US FDA-approved label, version 1458, February 12, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9aa6489-5a36-44ed-9512-b996833d82f7
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .